Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
- Adding GLP-1 to Insulin
- FDA Approves Fast-Acting Mealtime Insulin
- Is Thyroid Dysfunction Associated With Type 2 Diabetes?
- Canagliflozin and Cardiovascular, and Renal Events In Type 2 Diabetes
- Discontinuation of Low Dose Aspirin Can Lead To Risk Of Cardiovascular Events
- Insulin Pump vs. Insulin Injection: Which Is Best for Type 1 Children?
- Exclusive: Keith Campbell on the Past and Future of Diabetes Care
Letter from the Editor
This week insulin takes a front row in treating diabetes with the information on a new super rapid insulin. This insulin, discussed in this week’s item 2, gives flexibility at meal time that has been lacking for a lot of patients.
Also, as Animas leaves the insulin pump market, a new study discussed in item 6 shows the value of using pump therapy in children, and how we can all work to reduce hypoglycemia and A1c values.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: Semaglutide Gets FDA Vote of Approval
Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes. One member of the committee abstained.
This Week's Survey
When recommending an insulin pen to a patient, do you have sample pens to demonstrate how to use properly? Follow the link to see how you compare to your colleagues.
Tool: Patient Assistance Programs for Insulin
Eli Lilly & Company
Novo Nordisk
www.cornerstones4care.com/patient-assistance-program.html
Sanofi
www.sanofipatientconnection.com/patient-assistance-connection
Current Interview
R. Keith Campbell, RPh, MBA, CDE, FASHP, FAPhA, FAADE, is the former Associate Dean and is the Distinguished Professor in Diabetes Care/Pharmacotherapy at the Washington State University College of Pharmacy in Pullman, Washington.
Test Your Knowledge
Your 42-year-old, overweight patient was diagnosed with type 2 diabetes (A1C 7.7%) five months ago. You discussed the diagnosis with him, prescribed metformin, and provided lifestyle modification education resources. He missed his follow-up appointment, so you called him to schedule a return visit. At this appointment, he shares some of the positive lifestyle modifications he has made and that he has been taking his metformin consistently. He currently takes 2,000 mg metformin per day. At this visit, his A1C is 9.4%. All of the following are reasonable treatment options EXCEPT:
A. Metformin+ lifestyle modifications
B. Metformin + once-daily evening basal insulin dose + lifestyle modifications
C. Metformin + sulfonylurea+ lifestyle modifications
D. Metformin + GLP-1 receptor agonist + lifestyle modifications
Follow the link to see the correct answer.
Did You know: Fitbit Ionic Smartwatch to Show Blood Glucose Readings
ADexcom and Fitbit are working to put the CGM data on the new Fitbit ionic watch. This will make the fourth device that will have the blood glucose readings from the Dexcom sensor as it joins the Apple watch, ndroid Wear watch, and the iPhone. Initially, Fitbit Ionic will likely display data relayed from the Dexcom G5 phone app, just as Apple Watch and Android Wear currently do (“secondary display”). Over time, it’s possible that direct CGM-to-watch communication might be added – this would allow CGM data to be sent to the watch without the phone being present (“primary display”). Dexcom is already working on this direct communication with the Apple Watch, though there is no timeline on when it might be available. Wearers will be able to see health, activity, and glucose levels all on one device as well as learn exactly what exercise works best to lower blood sugars and what foods work best for as an individual. The device will even show how different medications affect daily blood sugars. Fitbit will also be working with Medtronic and Abbott’s new FDA-approved FreeStyle Libre Flash Glucose Monitoring System. — Fitbit newsflash Oct. 2017
Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.
A new formulation of Insulin Aspart can offer better glycemic control and may also be given after meals.
New study finds incidence of thyroid disorders in people with diabetes no higher than than those without.
Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.
Among long-term users, discontinuation of low-dose aspirin in absence of surgery or bleeding had a greater than 30% increased risk of cardiovascular events.
Insulin pumps therapy is associated with better glycemic control and fewer complications, new study suggests.
Quote of the Week!
“Great works are performed not by strength but by perseverance.”
…Samuel Johnson
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletter:
Jessica Quach, Doctor of Pharmacy Candidate; GA-PCOM School of Pharmacy
Kay Lynn Tran, Doctor of Pharmacy Candidate: Class of 2018; LECOM College of Pharmacy
Fabio Rodriguez, Doctor of Pharmacy Candidate: Class of 2018; LECOM College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com